ANN ARBOR, Mich., May 06, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today reported financial results for the first quarter ended March 31, 2025, and provided a business update.

New guidelines have been developed for the monitoring of patients with inflammatory bowel disease in an effort to prevent them going on to ...

Discover why Mirum Pharmaceuticals is a growth opportunity with billion-dollar pipeline potentials, near-term catalysts, and ...

ACG released new guidance for the management of malnutrition in patients with liver disease, including the newly renamed ...

Researchers and clinicians have developed major new guidelines for the monitoring of patients with inflammatory bowel disease ...

Actor Ben Darling will abseil 70 feet down the Pears Building at Hampstead’s Royal Free Hospital to thank staff after his life-saving ...

Zurich (Switzerland), April 28, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today ...

Mirum Pharmaceuticals, Inc. today announced that it will present data at three upcoming medical congresses. Digestive Disease Week (DDW) will be held in San Diego, May 3-6, 2025. The European ...

The global primary sclerosing cholangitis (PSC) market is on an impressive growth trajectory, with forecasts estimating a market valuation of USD 314.26 million by 2033. This robust expansion is ...

Ipsen’s elafibranor has shown promise as a treatment for primary sclerosing cholangitis (PSC), a rare liver disease that ...